A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Incyte Corporation
Karyopharm Therapeutics Inc
Incyte Corporation
M.D. Anderson Cancer Center
iOnctura
Incyte Corporation
AbbVie
Novartis
University of Washington
Fred Hutchinson Cancer Center
University Health Network, Toronto